Analysts Expect Gilead Sciences, Inc. (GILD) Will Announce Quarterly Sales of $5.38 Billion
Wall Street analysts predict that Gilead Sciences, Inc. (NASDAQ:GILD) will report sales of $5.38 billion for the current quarter, Zacks Investment Research reports. Nine analysts have made estimates for Gilead Sciences’ earnings. The highest sales estimate is $5.68 billion and the lowest is $5.20 billion. Gilead Sciences reported sales of $6.51 billion during the same quarter last year, which indicates a negative year-over-year growth rate of 17.4%. The firm is scheduled to issue its next earnings report on Thursday, October 25th.
According to Zacks, analysts expect that Gilead Sciences will report full year sales of $21.58 billion for the current year, with estimates ranging from $20.91 billion to $22.34 billion. For the next year, analysts anticipate that the company will report sales of $21.76 billion per share, with estimates ranging from $19.75 billion to $25.41 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping analysts’ consensus estimates of $1.56 by $0.35. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. The firm had revenue of $5.65 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same period in the previous year, the firm posted $2.56 EPS. The business’s quarterly revenue was down 20.9% on a year-over-year basis.
Gilead Sciences opened at $76.73 on Friday, Marketbeat.com reports. Gilead Sciences has a twelve month low of $64.27 and a twelve month high of $89.54. The company has a debt-to-equity ratio of 1.23, a quick ratio of 3.23 and a current ratio of 3.00. The stock has a market capitalization of $99.70 billion, a PE ratio of 8.96, a price-to-earnings-growth ratio of -5.86 and a beta of 1.03.
The company also recently declared a quarterly dividend, which will be paid on Thursday, September 27th. Investors of record on Friday, September 14th will be issued a dividend of $0.57 per share. The ex-dividend date is Thursday, September 13th. This represents a $2.28 annualized dividend and a yield of 2.97%. Gilead Sciences’s payout ratio is 26.64%.
In related news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Friday, June 1st. The shares were sold at an average price of $68.13, for a total transaction of $3,406,500.00. Following the transaction, the director now directly owns 3,067,762 shares in the company, valued at approximately $209,006,625.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 150,000 shares of company stock worth $10,839,500 over the last quarter. 1.30% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of GILD. Glenview Trust Co boosted its position in Gilead Sciences by 3.5% in the 2nd quarter. Glenview Trust Co now owns 87,467 shares of the biopharmaceutical company’s stock valued at $6,196,000 after buying an additional 2,944 shares during the period. Envestnet Asset Management Inc. boosted its position in Gilead Sciences by 589.1% in the 2nd quarter. Envestnet Asset Management Inc. now owns 585,817 shares of the biopharmaceutical company’s stock valued at $41,499,000 after buying an additional 500,802 shares during the period. Highstreet Asset Management Inc. boosted its position in Gilead Sciences by 13.0% in the 2nd quarter. Highstreet Asset Management Inc. now owns 48,756 shares of the biopharmaceutical company’s stock valued at $3,454,000 after buying an additional 5,621 shares during the period. ING Groep NV boosted its position in Gilead Sciences by 273.9% in the 2nd quarter. ING Groep NV now owns 322,734 shares of the biopharmaceutical company’s stock valued at $22,862,000 after buying an additional 236,424 shares during the period. Finally, Commerzbank Aktiengesellschaft FI boosted its position in Gilead Sciences by 11.8% in the 2nd quarter. Commerzbank Aktiengesellschaft FI now owns 425,180 shares of the biopharmaceutical company’s stock valued at $30,120,000 after buying an additional 44,970 shares during the period. Institutional investors own 77.59% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Read More: What is the NASDAQ?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.